Enhancing Capital LLC Invests $1.10 Million in Pfizer Inc. (NYSE:PFE)

Enhancing Capital LLC acquired a new position in shares of Pfizer Inc. (NYSE:PFE) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 41,600 shares of the biopharmaceutical company’s stock, valued at approximately $1,104,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Xponance Inc. boosted its position in shares of Pfizer by 4.2% during the 4th quarter. Xponance Inc. now owns 851,248 shares of the biopharmaceutical company’s stock worth $22,584,000 after purchasing an additional 34,344 shares in the last quarter. Generali Asset Management SPA SGR bought a new position in shares of Pfizer during the 4th quarter worth about $11,538,000. Horizon Investments LLC boosted its position in shares of Pfizer by 1.6% during the 4th quarter. Horizon Investments LLC now owns 82,602 shares of the biopharmaceutical company’s stock worth $2,156,000 after purchasing an additional 1,271 shares in the last quarter. Advisors Asset Management Inc. lifted its position in Pfizer by 8.6% in the 4th quarter. Advisors Asset Management Inc. now owns 748,468 shares of the biopharmaceutical company’s stock valued at $19,857,000 after acquiring an additional 59,283 shares in the last quarter. Finally, Brooktree Capital Management lifted its position in Pfizer by 1.2% in the 4th quarter. Brooktree Capital Management now owns 115,383 shares of the biopharmaceutical company’s stock valued at $3,061,000 after acquiring an additional 1,389 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Insider Activity at Pfizer

In other Pfizer news, Director Ronald E. Blaylock acquired 19,457 shares of Pfizer stock in a transaction that occurred on Thursday, February 13th. The stock was acquired at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the purchase, the director now owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. This represents a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 0.06% of the stock is owned by company insiders.

Analyst Ratings Changes

PFE has been the topic of several recent research reports. UBS Group dropped their price target on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research report on Wednesday, January 8th. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a research report on Wednesday, March 12th. StockNews.com cut shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, November 20th. Bank of America reaffirmed a “neutral” rating and issued a $29.00 price target on shares of Pfizer in a research report on Tuesday, December 10th. Finally, Truist Financial dropped their price target on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research report on Wednesday, December 18th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have given a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $31.92.

Pfizer Trading Up 1.3 %

Shares of PFE stock opened at $26.07 on Tuesday. The company has a 50 day moving average of $26.22 and a 200-day moving average of $27.10. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 12-month low of $24.48 and a 12-month high of $31.54. The firm has a market cap of $147.72 billion, a P/E ratio of 18.49, a PEG ratio of 0.64 and a beta of 0.61.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. During the same quarter last year, the business posted $0.10 EPS. Pfizer’s quarterly revenue was up 24.7% compared to the same quarter last year. Sell-side analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.